Akari Therapeutics CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview

Reuters

Feb 11

Akari <a href="https://laohu8.com/S/LENZ">Therapeutics</a> CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview

Akari Therapeutics plc (Nasdaq: AKTX), an oncology biotechnology company specializing in next-generation antibody drug conjugates (ADCs), recently participated in a Virtual Investor "What This Means" interview. CEO Abizer Gaslightwala discussed the company's expanded ADC pipeline, intellectual property strategy, and the recent introduction of AKTX-102, a new ADC candidate targeting CEACAM5-expressing solid tumors. Gaslightwala highlighted the scalability of Akari's PH1-powered ADC platform and its differentiated approach through novel antibody constructs and RNA-splicing payloads. The interview also covered the strategic importance of Akari's growing patent portfolio and the advancement of its lead program, AKTX-101, towards IND and CTA submissions and first-in-human studies. The Virtual Investor "What This Means" segment featuring Akari Therapeutics is now available here.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652425-en) on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610580859"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610580859\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610580859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610580859","market":"fut","top_or_hot":-1,"title":"Akari Therapeutics CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akari Therapeutics plc (Nasdaq: AKTX), an oncology biotechnology company specializing in next-generation antibody drug conjugates (ADCs), recently participated in a Virtual Investor \"What This Means\" interview. CEO Abizer Gaslightwala discussed the company's expanded ADC pipeline, intellectual property strategy, and the recent introduction of AKTX-102, a new ADC candidate targeting CEACAM5-expressing solid tumors. Gaslightwala highlighted the scalability of Akari's PH1-powered ADC platform and its differentiated approach through novel antibody constructs and RNA-splicing payloads. The interview also covered the strategic importance of Akari's growing patent portfolio and the advancement of its lead program, AKTX-101, towards IND and CTA submissions and first-in-human studies. The Virtual Investor \"What This Means\" segment featuring Akari Therapeutics is now available here.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652425-en) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akari Therapeutics CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkari Therapeutics CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akari Therapeutics plc (Nasdaq: AKTX), an oncology biotechnology company specializing in next-generation antibody drug conjugates (ADCs), recently participated in a Virtual Investor \"What This Means\" interview. CEO Abizer Gaslightwala discussed the company's expanded ADC pipeline, intellectual property strategy, and the recent introduction of AKTX-102, a new ADC candidate targeting CEACAM5-expressing solid tumors. Gaslightwala highlighted the scalability of Akari's PH1-powered ADC platform and its differentiated approach through novel antibody constructs and RNA-splicing payloads. The interview also covered the strategic importance of Akari's growing patent portfolio and the advancement of its lead program, AKTX-101, towards IND and CTA submissions and first-in-human studies. The Virtual Investor \"What This Means\" segment featuring Akari Therapeutics is now available here.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652425-en) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLTzC6l:1","article_id":"2610580859","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610580859","pubTimestamp":1770817514,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akari Therapeutics plc , an oncology biotechnology company specializing in next-generation antibody drug conjugates , recently participated in a Virtual Investor \"What This Means\" interview. CEO Abizer Gaslightwala discussed the company's expanded ADC pipeline, intellectual property strategy, and the recent introduction of AKTX-102, a new ADC candidate targeting CEACAM5-expressing solid tumors. Gaslightwala highlighted the scalability of Akari's PH1-powered ADC platform and its differentiated approach through novel antibody constructs and RNA-splicing payloads. The interview also covered the strategic importance of Akari's growing patent portfolio and the advancement of its lead program, AKTX-101, towards IND and CTA submissions and first-in-human studies. The Virtual Investor \"What This Means\" segment featuring Akari Therapeutics is now available here.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","AKTX":"Akari Therapeutics PLC","BK4007":"制药","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Akari Therapeutics首席执行官在虚拟投资者采访中强调ADC管道扩张","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"AKTX":0.9},"content_text":"Akari Therapeutics CEO Highlights ADC Pipeline Expansion in Virtual Investor Interview\n    \n\n        Akari Therapeutics plc (Nasdaq: AKTX), an oncology biotechnology company specializing in next-generation antibody drug conjugates (ADCs), recently participated in a Virtual Investor \"What This Means\" interview. CEO Abizer Gaslightwala discussed the company's expanded ADC pipeline, intellectual property strategy, and the recent introduction of AKTX-102, a new ADC candidate targeting CEACAM5-expressing solid tumors. Gaslightwala highlighted the scalability of Akari's PH1-powered ADC platform and its differentiated approach through novel antibody constructs and RNA-splicing payloads. The interview also covered the strategic importance of Akari's growing patent portfolio and the advancement of its lead program, AKTX-101, towards IND and CTA submissions and first-in-human studies. The Virtual Investor \"What This Means\" segment featuring Akari Therapeutics is now available here.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652425-en) on February 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}